U.S. FDA Accepts Dupilumab’s sBLA for BP for Priority Review
The U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for dupilumab (Dupixent, Sanofi & Regeneron) to treat adults with bullous pemphigoid (BP) for priority review. If approved, dupilumab would be the first and only targeted medicine to treat BP in the US. The FDA decision is expected by June […]